The primary goal of the newly proposed Transgenic and Chimeric Mouse Facility (TCMF) is to provide a reliable service to members of the University of Pittsburgh Cancer Institute (UPCI) and to others in the University of Pittsburgh scientific community. This service includes the generation of new transgenic and knockout mouse lines, derivation of existing lines via transfer of pre-implantation embryos, cryopreservation of mouse embryos. The TCMF uses state-of-the-art technologies and has staff with the technical expertise to provide these services. Another important aim of the TCMF is to provide consultations with UPCI investigators to assist in the design of experiments to modify the genetic composition of mice. These experiments are primarily transgenic and targeted mutagenesis experiments (knockouts and knockins). The consultations focus on the efficient design of DNA plasmids, containing transgene and gene targeting constructs, to ensure the success of an investigator's in vivo mouse experiments. As part of this assistance, the TCMF can provide a variety of different plasmids to ensure the accuracy of the DNA constructs. Finally, the TCMF will provide an education and training service to investigators wishing to learn and incorporate transgenic and gene targeting technologies into their own laboratories. Technologies provided There are five specific technical services that the TCMF provides to investigators: Pronuclear microinjection (PNM) ES cell electroporation (ESE) ES cell injection (ESM) Line derivation (DER) Embryo cryopreservation (CRY)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-19
Application #
7279253
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
19
Fiscal Year
2006
Total Cost
$38,825
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358

Showing the most recent 10 out of 1187 publications